Open AccessHigh prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates
Author(s) -
Jens Verheyen,
Chris Verhofstede,
Elena Knops,
Linos Vandekerckhove,
Axel Fun,
Diede Brunen,
Kenny Dauwe,
Annemarie M. J. Wensing,
Herbert Pfister,
Rolf Kaiser,
Monique Nijhuis
Publication year - 2010
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32833160fa
Subject(s) - protease , protease inhibitor (pharmacology) , virology , biology , drug resistance , hiv 1 protease , mutation , resistance mutation , population , reverse transcriptase , microbiology and biotechnology , human immunodeficiency virus (hiv) , polymerase chain reaction , medicine , genetics , viral load , enzyme , gene , antiretroviral therapy , environmental health , biochemistry
Bevirimat is the first drug of a new class of antivirals that hamper the maturation of HIV. The objective of this study was to evaluate the sequence variability of the gag region targeted by bevirimat in HIV subtype-B isolates.